- Awards are meant to support pilot projects or team science projects in multidisciplinary research focused on prostate cancer that aims to develop a new research direction, explore an innovative idea, test an unconventional — but potentially important — new hypothesis, or ascertain the feasibility of a new research approach.
- Pilot projects should be aimed at providing preliminary data to be used in a future R01 level grant application. Awards for the team science projects should result in preliminary data that can be used to create and submit a program project grant, for example a P01.
- An emphasis will be placed on funding high-risk/high-reward research with a high priority given to project innovation and potential for clinical impact.
- Partnership with a Brady Urological Institute faculty member is highly encouraged. Funds (up to $100,000 for one year for pilot projects and up to $200,000 for one year for team science projects) may be used for the salaries of staff or trainees (graduate students or postdoctoral fellows), equipment and/or research supplies. Faculty salaries are not allowable on these awards.
- Awards are granted for a 1-year period with the option of extending for 1 year with a scientific justification. At the conclusion of the first year (and the NCE period), a financial status report should be provided detailing utilization of funds. At the conclusion of the project, unspent funds should be returned to the Department of Urology.
- All faculty of the Johns Hopkins University may apply, whether or not they are members of the James Buchanan Brady Urological Institute or of the Sidney Kimmel Comprehensive Cancer Center.
- An investigator may hold only one pilot project award at a time.
- Fellows are not permitted to be principal investigators. A preference will be given to applications submitted by investigators who have not previously received research support through Patrick C. Walsh Prostate Cancer Research Fund.
- Awardees will be expected to provide a 500-word summary of their research plans, understandable to lay people, at the time of funding.
- At the completion of the award, you must email a two-page technical progress report and an additional 500-word progress summary (written in layman’s terms) to David “Brandy” Yeater at email@example.com.
- Awardees will be expected to present their progress at an annual scientific session, most likely at the Annual Department of Urology Donald S. Coffey Johns Hopkins Prostate Research Day.
- Publications generated as a result of funding support must acknowledge the Patrick C. Walsh Prostate Cancer Research Fund.
How to Apply
- Submit your grant application electronically using the Pilot Projects Registration Center.
- Applications should be simple and brief, and follow these guidelines:
- Page 1 of the application proposal should serve as the Title Page
- Title page plus Specific Aims, Background and Experimental Design sections together should not exceed five pages.
- Use Arial 11 pt. font, and 1/2” margins
- Merge complete application proposal, including all required materials, into one PDF document. Components must be in the following order:
Title Page – Project title, PI/Co-PIs, and department affiliations
Background – Including preliminary studies of applicant
Experimental Design – Please refer to previous publications of PI whenever possible
References/Works Cited – Pages for this section are not included in the five-page limit
Plan and timeline for the submission of a R01 level grant (for pilot projects) or a program project grant (for team science projects) – Please limit to one page
Biosketch form for all key personnel – Please use the current NIH biosketch format
Current and pending funding for PI and co-PI – Carefully indicate reasons for non-overlap if potential overlap exists
- Upload PDF application proposal to the Pilot Projects Registration Center
- Applications will be judged by our scientific advisory board, which is composed of senior faculty members from several departments at the Johns Hopkins University School of Medicine, as well as patient representatives.